United Therapeutics Corporation - Strategy, SWOT and Corporate Finance Report

United Therapeutics Corporation - Strategy, SWOT and Corporate Finance Report

  • Products Id :- B0D60D8B-AF0D-4907-B94D-7433A1ED9878
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

United Therapeutics Corporation-Strategy, SWOT and Corporate Finance Report


United Therapeutics Corporation-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Key Highlights

United Therapeutics Corporation (United Therapeutics or 'the company') is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life threatening conditions. The product portfolio of the company includes Remodulin Injection; Tyvaso (treprostinil) Inhalation Solution; Adcirca (tadalafil) Tablets; Orenitram (treprostinil) extended release tablets; PLX Cells; Replacement Lungs- Transplantation and Self-Injectable Prostacyclin Analogues- PAH. United Therapeutics sells its products through specialty pharmaceutical distributors in the US. The company operates in Europe, Israel and the Middle East, Asia and South and Central America. United Therapeutics is headquartered in Silver Spring, Maryland, the US.


- Detailed information on United Therapeutics Corporation required for business and competitor intelligence needs

- A study of the major internal and external factors affecting United Therapeutics Corporation in the form of a SWOT analysis

- An in-depth view of the business model of United Therapeutics Corporation including a breakdown and examination of key business segments

- Intelligence on United Therapeutics Corporation's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about United Therapeutics Corporation, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of United Therapeutics Corporation and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess United Therapeutics Corporation as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on United Therapeutics Corporation's business structure, strategy and prospects.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Company Snapshot 2

Table of Contents 5

United Therapeutics Corporation: Company Overview 9

United Therapeutics Corporation: Overview and Key Facts 9

United Therapeutics Corporation: Overview 9

United Therapeutics Corporation: Key Facts 9

United Therapeutics Corporation: Key Employees 10

United Therapeutics Corporation: Key Employee Biographies 11

United Therapeutics Corporation: Major Products and Services 12

United Therapeutics Corporation: Company History 13

United Therapeutics Corporation: Management Statement 16

United Therapeutics Corporation: Locations and Subsidiaries 19

United Therapeutics Corporation: Key Competitors 20

United Therapeutics Corporation: Company Analysis 21

United Therapeutics Corporation: Business Description 21

United Therapeutics Corporation: SWOT Analysis 23

United Therapeutics Corporation: SWOT Overview 23

United Therapeutics Corporation: Strengths 23

United Therapeutics Corporation: Weaknesses 24

United Therapeutics Corporation: Opportunities 24

United Therapeutics Corporation: Threats 25

United Therapeutics Corporation: Corporate Financial Deals Activity 27

United Therapeutics Corporation: Financial Deals Overview 27

United Therapeutics Corporation: Targets and Partners 29

United Therapeutics Corporation: Top Deals 2014-2018YTD 30

United Therapeutics Corporation: Advisors 31

United Therapeutics Corporation: Top Legal Advisors 31

United Th

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

select a license
Single User License
USD 175 INR 12250
Site License
USD 350 INR 24500
Corporate User License
USD 525 INR 36750



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com